Though it has only a single mechanism, the medication is provided as an oral formulation that has the potential to increase adherence and patient access to the medication
Most are mild and temporary
Arch Dermatol (2010) 146:125762
Thus, developing an oral GLP-1 medication could significantly increase adoption among women over the age of 35, likely the largest GLP-1 patient group
The rule would require [insert science here] testing, and If the manufacturer fails to comply with testing and record-keeping requirements, the proposed rule allows the FDA to declare that product as adulterated under the Federal Food, Drug, and Cosmetic Act.
# Retatrutide: How to Reconstitute and Take Your First Dose Retatrutide (LY3437943) is a triple agonist it hits GLP-1, GIP, and glucagon receptors simultaneously